Abstract
UK guidelines currently endorse only one course of brentuximab vedotin as second-line treatment for CD30+ CTCL. We demonstrate that re-treatment can be safe, tolerable and highly efficacious in selected patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
